146 results about "Lactococcus" patented technology

The invention relates to an animal feed composite microecologic agent. The invention is formed by mixing composite microorganism powders, oligose, an auxiliary protective vector and a flavor composition, and comprises the total mass percents of1.0-30% of the composite microorganism powders, 5.0-35% of the oligose, 35-70% of the auxiliary protective vector and 0.1-0.2% of vanillic aldehyde, wherein, the composite microorganism powders select one or the combination of more than one of lactobacillus, yeast, bacillus and lactococcus; the oligose selects one or the combination of more than one of oligoisomaltose, soybean oligosaccharides and inulin; the auxiliary protective vector selects one or the combination of more than one of cornstarch, corncob, rapeseed cake powders and maltodextrin. The invention has the advantage that: live bacteria and oligose contained in the invention have the effect for prominently improving microecologic environment of entire intestines and aiding in digestion, and the invention has a plurality of advantages of preventing and treating intestinal diseases, enhancing the utilization rate of digestion of feed, promoting animal to grow fast and eradicating antibiotic additives.

The present invention relates to a pharmaceutical composition which includes naturally occurring, non-transgenic isolated bacteria from the group of Lactococcus and Acinetobacter or fragments thereof or mixtures thereof, to such a bacterium as a medicament for the prevention and / or treatment of allergic or chronic inflammatory disorders and to a process for producing this composition.

The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from Lactococcus and useful as promoters. The invention further relates to vectors comprising the said nucleic acids and host cells transformed therewith. The invention also covers the use of host cells comprising the said nucleic acids or vectors for expressing heterologous or homologous proteins; and also for delivery, especially therapeutic delivery, of the said proteins to subjects.

The present invention is directed to a wound or tissue dressing comprising a bacteria having the property of producing lactic acid from sugars by fermentation of the sugars. The bacteria preferably belongs to the family of lactic acid bacteria. The family of lactic acid bacteria refers to any bacteria belonging to a genus selected from the group consisting of Carnobacterium, Enterococcus, Lactobacillus, Lactococcus, Leuconostoc, Oenococcus, Pediococcus, Streptococcus, Tetragenococcus, Vagococcus and Weissella. There is also provided a wound or tissue dressing comprising an absorbent compound for absorbing wound exudate, wherein said wound or tissue dressing is attached to or comprises a lactic acid bacterium. The utility of the present invention is demonstrated by use of the wound or tissue dressings in methods for treating a wound or damaged tissue in an individual, said method comprising the steps of contacting said wound or damaged tissue with the wound or tissue dressing according to the invention, thereby treating the wound or damaged tissue. The treatment results in healing of the wound or in accelerated healing of the wound. There is also provided the use of a lactic acid bacteria in the manufacture of a wound or tissue dressing for treating or accelerating the healing of a wound in an individual.

The present invention provides an equol-producing lactic acid bacteria-containing composition comprising, as an essential component thereof, a lactic acid bacterial strain belonging to the genus Lactococcus having an ability to utilize at least one daidzein compound selected from the group consisting of daidzein glycosides, daidzein, and dihydrodaidzein to produce equol. Such a composition is effective for the prevention and alleviation of malaise inclusive of climacteric disturbance in middle-aged and elderly women for which no effective prophylactic method or alleviating means has heretofore been available.

The invention provides a microbial freezing drying protective agent using stachyose as one of main components in the protective agent. The protective agent consists of 0.8-3.5% of stachyose, 0.1-0.6%of sodium glutamate, 0.4-1.5% of galactose and 6-15% of skim milk powder. In the invention, the stachyose is applied to freeze, dry and protect strains and used as one of components of a freeze-dryingprotective agent so as to widen the application of the stachyose. Advantages of the stachyose, sodium glutamate and the like are mutually complemental to form favorable combinations of the freeze-drying protective agent. The invention has higher freeze-drying protective efficiency and stable protective effect to various bifidobacterium such as bifidobacterium breve, bifidobacterium adolesentis and the like and various lactobacillus such as lactic acid bacillus, lactococcus and the like. The invention solves the problems that freeze-drying protective agent is complicated, and the differences of protective effects are great in the study of microbial formulations and provides favorable compositions of the protective agent for the preservation of probiotics such as bifidobacterium, lactobacillus, saccharomycetes and the like, thereby being beneficial to preserving the strain stably.

A complete nutritional composition comprising Lactococcus strains or probiotic is provided for reducing the symptoms of allergies in different groups of patients such as allergies originating from food allergens in young children or infants and respiratory allergens in children, adults and household pets. Preferably the composition reduces symptoms of allergies (secondary prevention) while not significantly affecting sensitization (primary prevention). The composition comprises a probiotic of the genus Lactococcus.

The invention provides a sauerkraut (Direct Vat Set) DVS. Five lactobacillus production leavens such as lactobacillus plantarum, pediococcus acidilactici, leuconostoc mesenteroides, lactic lactococcus, lactobacillus brevis, and the like, are firstly prepared; the viable count of all production leavens is not less than 10<9> / ml; subsequently, the five lactobacillus production leavens are frozen dryly; according to the weight portions of the dryly frozen bacteria powder, 3-5 of lactobacillus plantarum, 2-4 of pediococcus acidilactici, 1-3 of leuconostoc mesenteroides, 1-3 of lactic lactococcus and 3-5 of lactobacillus brevis are taken and uniformly mixed so as to obtain the mixed dryly frozen leaven powder. The product of the invention can obviously shorten the fermentation period of the sauerkraut, lead the product to have acid bitterness and good taste, greatly reduce the content of the nitrite in the product, improve the edible safety of the product, and lead the yield of the sauerkraut to be improved from about 30% of natural fermentation to more than 40% at the same time.

The invention relates to a recombinant Lactococcus strain, with environmentally limited growth and viability. More particularly, it relates to a recombinant Lactococcus that can only survive in a medium, where well-defined medium compounds are present. A preferred embodiment is a Lactococcus that may only survive in a host organism, where such medium compounds are present, but cannot survive outside the host organism in the absence of such medium compounds.

The invention discloses a preparation method of fermented tea and the fermented tea. The preparation method of the fermented tea, disclosed by the invention, comprises the following steps: fermentingcrude tea or finished-product tea by adopting probiotic bacterium liquid; after fermenting, drying tea leaves to obtain the fermented tea, wherein the probiotic bacterium liquid contains at least oneof lactobacillus, lactococcus, saccharomyces cerevisiae, bifidobacterium and acetic acid bacteria. The preparation method disclosed by the invention has a simple technology and is easy to operate; theprepared fermented tea has original appearance characteristics of the tea leaves and also meets a traditional tea brewing habit; the fermented tea also has a health-care function and special mouthfeel and flavor of the tea leaves and a probiotic fermented product.

The invention discloses a compound microbial agent for low-temperature fermentation of straws. The compound microbial agent comprises trichoderma viride, aspergillus niger, bacillus subtilis, lactococcus, pediococcus acidilactici and bacillus circulans. In order to prolonging normal-temperature storage time of the compound microbial agent, the compound microbial agent further comprises auxiliary materials including a bacterium preserving agent, a carrier, an antioxidant, deionized water, a water retaining agent and the like. By application of the compound microbial agent for low-temperature fermentation of straws, the straws can be decomposed and blackened about 12 days under the low-temperature condition of 4-15 DEG C, the straws are basically thoroughly decomposed at a high speed; due to addition of the auxiliary materials including the bacterium preserving agent, the carrier, the antioxidant, the water retaining agent and the like into the compound microbial agent for low-temperature fermentation of the straws, the compound microbial agent can be stored for a long time at the normal temperature.

The present invention is directed to a wound or tissue dressing comprising a bacteria having the property of producing lactic acid from sugars by fermentation of the sugars. The bacteria preferably belongs to the family of lactic acid bacteria. The family of lactic acid bacteria refers to any bacteria belonging to a genus selected from the group consisting of Carnobacterium, Enterococcus, Lactobacillus, Lactococcus, Leuconostoc, Oenococcus, Pediococcus, Streptococcus, Tetragenococcus, Vagococcus and Weissella. There is also provided a wound or tissue dressing comprising an absorbent compound for absorbing wound exudate, wherein said wound or tissue dressing is attached to or comprises a lactic acid bacterium. The utility of the present invention is demonstrated by use of the wound or tissue dressings in methods for treating a wound or damaged tissue in an individual, said method comprising the steps of contacting said wound or damaged tissue with the wound or tissue dressing accordingto the invention, thereby treating the wound or damaged tissue. The treatment results in healing of the wound or in accelerated healing of the wound. There is also provided the use of a lactic acid bacteria in the manufacture of a wound or tissue dressing for treating or accelerating the healing of a wound in an individual.

The invention relates to a silage inoculant and a preparation method and application of the silage inoculant. The silage inoculant is prepared by respectively fermenting lactobacillus plantarum, bacillus subtilis and lactococcus and mixing the obtained fermentation broth, wherein the ratio of numbers of colony-forming units of lactobacillus plantarum to bacillus subtilis to lactococcus lactis in the mixed fermentation broths is (90-96) to (3.5-6) to (0.5-4), and the total number of colony-forming units is 0.8*10<12>-1.2*10<12>CFU / ml. Various lactic acid bacteria in the fungicide have a high synergistic effect, and form a stable eco-system, and non-sterile natural raw materials can be quickly propagated and colonized to hold advantages, so that large amounts of lactic acid are quickly generated, the pH value of fermented materials is reduced, the fermentation quality of a fodder is improved, the nutritional value and the palatability of the fodder are improved, the application is simple and easy, and the cost is low.

Disclosed is an agent for reducing visceral fat, which comprises a cell of a lactic acid bacterium, particularly a lactic acid bacterium belonging to the genus Lactobacillus or Lactococcus and / or a culture of the cell as an active ingredient. The agent can ameliorate the disease condition of metabolic syndrome which is a combination of risk factors including hypertension, hyperlipemia, impaired glucose tolerance and the like, and can also reduce the accumulation of visceral fat. Further disclosed is a food / beverage or feed comprising the agent.

Methods of enhancing the growth rate and / or controlling the metabolic activity of lactic acid bacteria and of improving the shelf life and / or the quality of an edible product using lactic acid bacterial organisms which are defective in their pyruvate metabolism. There is also provided starter culture compositions comprising such defective lactic acid bacteria as helper organisms and lactic acid bacterial starter culture strains. Useful helper organisms are Lactococcus strains which are defective with respect to pyruvate formate lyase (Pfl) and / or lactate dehydrogenase (Ldh) activity. The helper organisms may overexpress a gene coding for an NAD+ regenerating enzyme such as NADH oxidase encoded by nox gene.

The invention relates to the fields of genetic engineering and biomedicine, and more specifically relates to a biomarker of schizophrenia and its application. The invention discloses a marker of schizophrenia and its application in preparing a kit for diagnosing schizophrenia, and also discloses a kit for detecting the marker. The schizophrenia markers disclosed in the present invention include Prevotella, Succinivibrio, Fusobacterium, Lactobacillus, and Megasphaera , Acidaminococcus, Citrobacter, Phascolarctobacterium, Coprococcus, Roseburia, Blautia 11 species At least 5 of the microorganisms. The marker provided by the invention can judge schizophrenia and normal people, the AUC is above 0.81, has good diagnostic efficiency, and can be used to prepare a kit for effectively diagnosing schizophrenia.

The present invention relates to a method for producing a fermented milk, including: performing fermentation using both bacteria belonging to the genus Bifidobacterium and bacteria belonging to the genus Lactococcus as lactic acid bacteria, wherein the bacteria belonging to the genus Lactococcus have the following bacteriological properties: (1) fermentability which curdles a 10% (W / W) reconstituted skim milk medium when cultivated at a temperature of 25° C. to 37° C. for 16 hours; (2) Bifidobacterium longum growth-promoting properties which lead to a viable count of Bifidobacterium longum of 5×108 CFU / g or more, when co-cultivated with Bifidobacterium longum in the 10% (W / W) reconstituted skim milk medium until the pH thereof is 4.4 to 4.6; and (3) Bifidobacterium longum survivability-improving properties during storage, which lead to a survival rate of Bifidobacterium longum of 30% or more, after co-cultivation with Bifidobacterium longum in the 10% (W / W) reconstituted skim milk medium until the pH thereof is 4.4 to 4.6, rapid cooling, and two weeks storage at 10° C., and also relates to a fermented milk prepared by the production method.

A new type of cryoprotective agents that are useful for retaining the viability and metabolic activity of frozen or freeze-dried microbial cultures, is disclosed. The cryoprotective agent comprises compounds involved in biosynthesis of nucleic acids. Methods for the preparation as well as the uses of such cultures are given. Such cultures are useful as starter cultures in the manufacturing of food and feed products. Starter cultures of the invention include culture of lactic acid bacteria, e.g. Lactococcus species as well as other species.

The present invention belongs to the field of microorganism, and specially relates to a powdered yoghurt starter culture without additional milk sources and a preparation method and application thereof. Yogurt fermentation powder contains base materials composed of sucrose, glucose, whole milk powder and at least one of probiotic flavor powder, skimmed milk powder, soybean protein isolate, rice powder, wheat germ powder or fruit powder, and strain powder composed of streptococcus thermophilus, lactobacillus bulgaricus, and at least one of bifidobacteria, lactococcus or yeast. The yogurt fermentation powder is prepared by mixing the base material powder prepared by granulating, mesh screening and drying with the compound strain powder. The yogurt fermentation powder is highly soluble in water, and can be fermented directly at 35-45 DEG C to produce yogurt without the need of the additional milk sources. The yogurt produced by using the yogurt fermentation powder is strong in taste, high in live bacteria number, uniform in quality, and free from additive, and is fresh and healthy.

The invention relates to a lactococcus garviea bacteriocin, a preparing method thereof and an application thereof. The high-yield actococcus garviea bacteriocin can be obtained in the mode that lactococcus garviea is subjected to fermented cultivation, and then the bacteriocin in the cultivating-fermenting liquid is extracted with a pH adsorption method; more than 800 mg of the lactococcus garviea bacteriocin can be prepared through 1 L of the fermenting liquid. The lactococcus garviea bacteriocin has quite high broad-spectrum bacteriostasis capacity and has a quite high inhibiting effect on some gram negative bacteria, some gram positive bacteria, yeast and mould causing human diseases and food spoilage. The lactococcus garviea bacteriocin has the effect of treating and preventing acute and chronic enteritis.

A mutant of Lactococcus lactis spp. lactis, which produces lactate at high volumetric and specific productivity as well as high amounts of lactate dehydrogenase, as well as the use of said strain, and a method for producing lactate, as well as the use of the lactate thus produced.

The invention belongs to the field of foods and particularly relates to a method for directional screening of probiotics based on a pickled vegetable fermentation system. The screening method comprises the steps that 1, low-salt normal-temperature directional screening is conducted on the lactococcus of lactic acid; 2, low-salt low-temperature directional screening is conducted on Weissella; 3, medium-low-temperature low-salt screening is conducted on leuconostoc mesenteroides; 4, high-salt normal-temperature screening is conducted on plant lactobacillus. The probiotics obtained by means of the method based on the pickled vegetable fermentation system is high in safety and can be directly used in related health-care products healthy to a human body. By means of the method, different fermentation conditions can be designed by utilizing the change rule of a strain structure in the process of pickled vegetable fermentation, and the probiotic lactic bacteria can be directionally screened out at the specific fermentation stage under the conditions. The method is relatively simple and convenient, and a lot of separation and purification work can be avoided. Actually required probiotics can be blind selected from the pickled vegetable fermentation system with a complex strain structure, and corresponding actual application of the directionally screened probiotics can be directly performed according to respective beneficial functions.

The present invention relates to bacteria of a genus Lactococcus having bacteriological properties of: (1) fermentability which curdles a 10% (W / W) reconstituted skim milk medium when cultivated at a temperature of 25° C. to 37° C. for 16 hours; (2) Bifidobacterium longum growth-promoting properties which lead to a viable count of Bifidobacterium longum of 5×108 CFU / g or more, when co-cultivated with Bifidobacterium longum in the 10% (W / W) reconstituted skim milk medium, until the pH thereof is 4.4 to 4.6; and (3) Bifidobacterium longum survivability-improving properties during storage, which lead to a survival rate of Bifidobacterium longum of 30% or more, after co-cultivation with Bifidobacterium longum in the 10% (W / W) reconstituted skim milk medium until the pH thereof is 4.4 to 4.6, rapid cooling, and two weeks storage at 10° C.

The invention provides a recombination lactic acid galactococcus method of expessing pig transmissible gastroenteristis virus mutation S protein, which comprises the following steps: designing double primers according to the total gene order of pig Transmissible gastroenteristis virus S protein and gene fusion characteristic of expressing the carrier plasmid; proceeding PCR; getting the 2007bp destination fragments of four main antigen sites with TGEV S gene; connecting with the carrier plasmid PNZ8112 of secretory expression; getting into the host lactic acid galactococcus NZ9000 cell by electric conversion; expressing under the inducing of nisin. The invention constructs the expression carrier system of coronaviridae TGEV S mutein lactic acid galactococcus, which expresses about 66KDa destination protein of four main antigen sites with TGEV. Immunological ink mist experiment and indirect immunological fluorescein test indicate that the exogenesis protein is able to react with TGEV immunological serum and the recombination S protein has the same antigenic as TGEV natural antigenic.

The invention relates to novel I-type diabetes resisting recombination lactic acid bacteria and application thereof, belongs to the field of biological medicine, and discloses an I-type diabetes resisting vaccine with lactococcus lactics as a carrier and a preparing method and application of I-type diabetes resisting vaccine. A micro genetic technology platform of a laboratory is used, the recombination lactococcus lactics vaccine with lactococcus lactics as the carrier, and the recombination lactococcus lactics vaccine expresses fusion protein HSP65-6IA2P2 after induction. The correct expression of the fusion protein vaccine is detected through Western blot authentication. It is proved through in-vivo animal experiments that the vaccine can remarkably reduce the occurrence of NOD mouse diabetes through an oral administration way, can perform the function of controlling I-type diabetes and has good clinical application prospects on preventing diabetes.

The invention relates to a novel recombinant lactobacillus resisting diabetes mellitus type 1 and application thereof and belongs to the field of biomedicine and discloses a diabetes mellitus type 1 resistant vaccine using Lactococcus lactics as a vector and apreparation method and application thereof. A recombinant Lactococcus lactics vaccine using Lactococcus lactics as a vector and induced to express fusion protein HSP65-6IA2P2 is built by using a micro gene technology platform of the lab. The correct expression of a fusion protein vaccine is detected by Western blot analysis. In-vivo animal tests show that the vaccine can be orally administered to give significant reduction in the occurrence of diabetes in NOD (non-obese diabetic) mice and to prevent diabetes mellitus type 1, and has a promising clinical application prospect in terms of preventing diabetes.

The invention relates to a method for improving the digestibility and assimilability of fibres and / or cereals in a monogastric herbivorous animal comprising the step of administering to said monogastric herbivorous animal an effective amount of at least one strain of bacterium selected fromselected from the group consisting of strains of bacteria of the genera Lactobacillus, Lactococcus, Propionibacterium, Bifidobacterium and Bacillus. The invention also relates to a feed supplement for a monogastric herbivorous animal comprising at least one strain of bacterium selected fromselected from the group consisting of strains of bacteria of the genera Lactobacillus, Lactococcus, Propionibacterium, Bifidobacterium and Bacillus.

The present invention provides an oral vaccine against a bacterial infectious disease (e.g., typhoid fever, cholera, or dysentery). The oral vaccine of the present invention is a capsule formulation in which a transformed microorganism that expresses a flagellin antigen protein or that secretes a flagellin antigen protein out of the cell of the microorganism is encapsulated with an acid-resistant membrane. Examples of the microorganism include intestinal bacteria belonging to the genus Bifidobacterium, the genus Lactobacillus, the genus Lactococcus, and the like. The form of the capsule formulation may be any one of a seamless capsule formulation, a soft capsule formulation, and a hard capsule formulation.